SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerrys second-quarter results beat expectations and lifted its full-year outlook, with record QNX performance and the first Alloy Kore design win drawing particular attention. Traders are largely positive on the operational progress but debate why the shares are weak despite the results, citing a cautious next-quarter outlook, valuation concerns, and broader market pressure.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlist shares are drawing attention after the USITC instituted an investigation into alleged patent infringement by Micron and several downstream companies, with the community reacting to the development as added leverage for Netlist. Traders are broadly bullish and speculate it could lead to licensing or settlement talks, though the investigation is not a finding of infringement and some caution that the outcome remains uncertain.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Goldman Sachs return to a Buy rating has drawn attention, citing improving Amtagvi launch execution and margins. Traders are also watching for revised revenue guidance and NSCLC data, with optimism about the commercial and pipeline outlook tempered by frustration over the guidance delay and concern about biotech-sector weakness.

McDonald's Corp. engages in the operation and franchising of restaurants. The firm operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. Its products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, and McCafe beverages. The company was founded by Raymond Albert Kroc on April 15, 1955 and is headquartered in Chicago, IL.

McDonald`s Corp

McDonald's Corp

McDonalds shares sold off after its investor-day outlook pointed to persistently high inflation, flat industry traffic and slightly negative U.S. sales for the quarter, while its NEXT strategy calls for substantial restaurant and franchisee investment. Traders are split between viewing the decline as a buying opportunity and worrying that weak traffic, affordability pressures and execution challenges could prolong the slump.

Redwire Corp. engages in the development and provision of space and defense technologies and mission-critical solutions for government, commercial, and civil customers. Its offerings include spacecraft platforms, space infrastructure, avionics, sensors and payloads, power generation systems, radio frequency systems, microgravity research and manufacturing technologies, autonomous systems, optical sensors, and digital engineering solutions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwires selection for a Space Systems Command NITE-STAR IDIQ contract valued at more than $980 million is drawing attention, with traders weighing its national-security business potential against the fact that the multi-award contract guarantees no revenue. Reactions are split between optimism about the award and skepticism that it will translate into near-term orders or meaningful sales.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Positive registrational-trial results for Kyvernas CAR-T therapy miv-cel in stiff person syndrome, alongside encouraging longer-term myasthenia gravis data, are driving attention. Many traders view the results as strengthening the path toward an FDA filing and potential first approval of an autoimmune CAR-T therapy, while others point to sharp post-news volatility, serious adverse events and possible dilution as reasons for caution.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtions claimed milestone of reaching 30 entangled logical qubits on its commercial system is driving attention, with traders highlighting its significance in the neutral-atom quantum race. Many are bullish, though some question the practical significance without further error-correction details and are frustrated that the news has not translated into a stronger stock move amid broader market pressure.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Metas VR and AI hardware showcase has renewed attention on Unitys existing relationship with Metas VR platform, while traders cite unusual call-option activity and speculate about a Unity-related announcement. Some caution that no new Unity deal or announcement has been confirmed.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns upcoming earnings are drawing attention as traders weigh AI-driven memory demand, tight DRAM/NAND supply, and stronger pricing against the stocks sharp run-up. Many expect a strong report, while others warn of elevated expectations, profit-taking, and a possible sell-the-news pullback.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Rising Treasury yields and expectations for further Fed tightening are the main concerns weighing on SPY, with traders linking higher borrowing costs to market weakness. The community is split between expecting more downside and treating the pullback as a buying opportunity, with some anticipating a rebound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy PTC Completes Acquisition of ST-920 Fabry Disease Gene TherapyPR NewswireWARREN, N.J., Sept. 21, 2026 Completion of BLA submission expected in Q4 2026 WARREN, N.J., Sept. 21, 2026 /PRNewswire/ --PTC Therapeutics, Inc., (NASDAQ: PTCT...

ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?

ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

PTC Therapeutics to Participate in Upcoming Investor Conferences

PTC Therapeutics to Participate in Upcoming Investor Conferences PTC Therapeutics to Participate in Upcoming Investor Conferences PR Newswire WARREN, N.J., Aug. 27, 2026 WARREN, N.J., Aug. 27, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak...

KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak

Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.

Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?

Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.

PTC Therapeutics Announces New Sephience (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

PTC Therapeutics Announces New Sephience (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile PTC Therapeutics Announces New Sephience (sepiapterin) Data Reinforcing Broad Patient Benefits...

PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'

PTC Therapeutics plans to acquire Sangamo's ST-920 Fabry disease program for $111 million upfront, with FDA filing expected in Q4 2026.read more...

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program PR Newswire WARREN, N.J., Aug. 12, 2026 Planned acquisition leverages existing regulatory and commercial...

PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PTC Therapeutics (PTCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

PTC Therapeutics Inc

PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided

Equity

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

PTCT PTC Therapeutics Inc

Fundamentals

Latest PTCT News